2024
Ogiji, E. D., Aboheimed, N., Ross, K., Voller, C., Siner, R., Jensen, R. L., . . . Carr, D. F. (2024). Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review.. Current opinion in allergy and clinical immunology, 24(4), 218-227. doi:10.1097/aci.0000000000000993DOI: 10.1097/aci.0000000000000993
Defining the importance of mitochondrial genotype in determining individual variation in hepatic fatty acid oxidation and dysregulation (Thesis / Dissertation)
Jensen, R. (2024, June 19). Defining the importance of mitochondrial genotype in determining individual variation in hepatic fatty acid oxidation and dysregulation.
Liew, F., Efstathiou, C., Fontanella, S., Richardson, M., Saunders, R., Swieboda, D., . . . ISARIC investigators. (2024). Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease.. Nature immunology, 25(4), 607-621. doi:10.1038/s41590-024-01778-0DOI: 10.1038/s41590-024-01778-0
Gardner, J., Hammond, S., Jensen, R., Gibson, A., Krantz, M. S., Ardern-Jones, M., . . . Naisbitt, D. J. (2024). Glycolysis: An early marker for vancomycin-specific T-cell activation.. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 54(1), 21-33. doi:10.1111/cea.14423DOI: 10.1111/cea.14423
2023
Sidhu, J. K., Siggins, M. K., Liew, F., Russell, C. D., Uruchurtu, A. S. S., Davis, C., . . . ISARIC4C investigators. (2023). Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.. The Journal of infectious diseases, jiad590. doi:10.1093/infdis/jiad590DOI: 10.1093/infdis/jiad590
Michael, B. D., Dunai, C., Needham, E. J., Tharmaratnam, K., Williams, R., Huang, Y., . . . Menon, D. K. (2023). Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.. Nature communications, 14(1), 8487. doi:10.1038/s41467-023-42320-4DOI: 10.1038/s41467-023-42320-4
COVID-19 Host Genetics Initiative. (2023). A second update on mapping the human genetic architecture of COVID-19.. Nature, 621(7977), E7-E26. doi:10.1038/s41586-023-06355-3DOI: 10.1038/s41586-023-06355-3
Goldswain, H., Dong, X., Penrice-Randal, R., Alruwaili, M., Shawli, G. T., Prince, T., . . . Hiscox, J. A. (2023). The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.. Genome biology, 24(1), 47. doi:10.1186/s13059-023-02881-5DOI: 10.1186/s13059-023-02881-5
4 Clinical consequences of drug-induced mitochondrial dysfunction (Chapter)
Jensen, R. L., Kiy, R. T., Bin Dayel, F. F., & Chadwick, A. E. (2023). 4 Clinical consequences of drug-induced mitochondrial dysfunction. In Mitochondrial Intoxication (pp. 77-100). Elsevier. doi:10.1016/b978-0-323-88462-4.00026-2DOI: 10.1016/b978-0-323-88462-4.00026-2
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N., . . . Openshaw, P. J. M. (2023). SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBIOMEDICINE, 87. doi:10.1016/j.ebiom.2022.104402DOI: 10.1016/j.ebiom.2022.104402
2022
Clinical consequences of drug-induced mitochondrial dysfunction (Chapter)
Jensen, R. L., Kiy, R. T., Bin Dayel, F. F., & Chadwick, A. E. (2023). Clinical consequences of drug-induced mitochondrial dysfunction. In Mitochondrial Intoxication (pp. 77-100). Elsevier. doi:10.1016/b978-0-323-88462-4.00026-2DOI: 10.1016/b978-0-323-88462-4.00026-2
Vink, E., Davis, C., MacLean, A., Pascall, D., McDonald, S. E., Gunson, R., . . . Ho, A. (2022). Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study. OPEN FORUM INFECTIOUS DISEASES, 9(11). doi:10.1093/ofid/ofac531DOI: 10.1093/ofid/ofac531
Siggins, M. K., Davies, K., Fellows, R., Thwaites, R. S., Baillie, J. K., Semple, M. G., . . . ISARIC4C Investigators. (2022). Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology. doi:10.1111/imm.13585DOI: 10.1111/imm.13585
Defining the importance of the mitochondrial genome in the role of NAFLD using 3D in vitro transmitochondrial cybrid steatotic and fibrotic models (Conference Paper)
Jensen, R., Chadwick, A., Sharma, P., & Williams, D. (2022). Defining the importance of the mitochondrial genome in the role of NAFLD using 3D in vitro transmitochondrial cybrid steatotic and fibrotic models. In TOXICOLOGY LETTERS Vol. 368 (pp. S54). doi:10.1016/j.toxlet.2022.07.165DOI: 10.1016/j.toxlet.2022.07.165
Keeling, M. J., Dyson, L., Guyver-Fletcher, G., Holmes, A., Semple, M. G., Tildesley, M. J., & Hill, E. M. (2022). Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. STATISTICAL METHODS IN MEDICAL RESEARCH, 31(9), 1716-1737. doi:10.1177/09622802211070257DOI: 10.1177/09622802211070257
Norris, T., Razieh, C., Zaccardi, F., Yates, T., Islam, N., Gillies, C. L., . . . Khunti, K. (2022). Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. HEART, 108(15), 1200-1208. doi:10.1136/heartjnl-2021-320047DOI: 10.1136/heartjnl-2021-320047
Heaton, B. J., Jensen, R. L., Line, J., David, C. A. W., Brain, D. E., Chadwick, A. E., & Liptrott, N. J. (2022). Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1. BIOMEDICINE & PHARMACOTHERAPY, 150. doi:10.1016/j.biopha.2022.112999DOI: 10.1016/j.biopha.2022.112999
Relph, K. A., Russell, C. D., Fairfield, C. J., Turtle, L., de Silva, T. I., Siggins, M. K., . . . Young, P. (2022). Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 9(5). doi:10.1093/ofid/ofac179DOI: 10.1093/ofid/ofac179
Narhi, F., Moonesinghe, S. R., Shenkin, S. D., Drake, T. M., Mulholland, R. H., Donegan, C., . . . Docherty, A. B. (2022). Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. LANCET DIGITAL HEALTH, 4(4). Retrieved from https://www.webofscience.com/
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., . . . Screaton, G. R. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. Cell, 185(3), 467-484.e15. doi:10.1016/j.cell.2021.12.046DOI: 10.1016/j.cell.2021.12.046
Knight, S. R., Gupta, R. K., Ho, A., Pius, R., Buchan, I., Carson, G., . . . Harrison, E. M. (2022). Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. THORAX, 77(6), 606-615. doi:10.1136/thoraxjnl-2021-217629DOI: 10.1136/thoraxjnl-2021-217629
2021
Niemi, M. E. K., Karjalainen, J., Daly, M., Ganna, A., Mehtonen, J., Cordioli, M., . . . Dopazo, X. (2021). Mapping the human genetic architecture of COVID-19. NATURE, 600(7889), 472-+. doi:10.1038/s41586-021-03767-xDOI: 10.1038/s41586-021-03767-x
de, S. T. I., Liu, G., Lindsey, B. B., Dong, D., Moore, S. C., Hsu, N. S., . . . Dong, T. (2021). The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. ISCIENCE, 24(11). doi:10.1016/j.isci.2021.103353DOI: 10.1016/j.isci.2021.103353
Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., . . . Wilson, S. J. (2021). A prenylated dsRNA sensor protects against severe COVID-19. SCIENCE, 374(6567). doi:10.1126/science.abj3624DOI: 10.1126/science.abj3624
Hurst, E. A., Mellanby, R. J., Handel, I., Griffith, D. M., Rossi, A. G., Walsh, T. S., . . . Russell, C. D. (2021). Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. BMJ OPEN, 11(10). doi:10.1136/bmjopen-2021-055435DOI: 10.1136/bmjopen-2021-055435
Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., . . . Ho, A. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. LANCET MICROBE, 2(8), E354-E365. doi:10.1016/S2666-5247(21)00090-2DOI: 10.1016/S2666-5247(21)00090-2
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., . . . Semple, M. G. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. LANCET, 398(10296), 223-237. Retrieved from https://www.webofscience.com/
Docherty, A., Mulholland, R., Lone, N. I., Cheyne, C., De Angelis, D., Diaz-Ordaz, K., . . . Semple, M. (2021). Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 773-785. doi:10.1016/S2213-2600(21)00175-2DOI: 10.1016/S2213-2600(21)00175-2
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. (Journal article)
Drake, T. M., Fairfield, C. J., Pius, R., Knight, S. R., Norman, L., Girvan, M., . . . ISARIC4C Investigators. (2021). Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.. The Lancet. Rheumatology, 3(7), e498-e506. doi:10.1016/s2665-9913(21)00104-1DOI: 10.1016/s2665-9913(21)00104-1
Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178DOI: 10.1002/oby.23178
Bloom, C. I., Drake, T. M., Docherty, A. B., Lipworth, B. J., Johnston, S. L., Nguyen-Van-Tam, J. S., . . . Openshaw, P. J. M. (2021). Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 699-711. doi:10.1016/S2213-2600(21)00013-8DOI: 10.1016/S2213-2600(21)00013-8
Leclerc, Q. J., Fuller, N. M., Keogh, R. H., Diaz-Ordaz, K., Sekula, R., Semple, M. G., . . . Knight, G. M. (2021). Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC HEALTH SERVICES RESEARCH, 21(1). doi:10.1186/s12913-021-06509-xDOI: 10.1186/s12913-021-06509-x
Gupta, R. K., Harrison, E. M., Ho, A., Docherty, A. B., Knight, S. R., van Smeden, M., . . . Noursadeghi, M. (2021). Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. LANCET RESPIRATORY MEDICINE, 9(4), 349-359. doi:10.1016/S2213-2600(20)30559-2DOI: 10.1016/S2213-2600(20)30559-2
Thwaites, R. S., Sanchez Sevilla Uruchurtu, A., Siggins, M. K., Liew, F., Russell, C. D., Moore, S. C., . . . ISARIC4C investigators. (2021). Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19.. Science Immunology, 6(57). doi:10.1126/sciimmunol.abg9873DOI: 10.1126/sciimmunol.abg9873
Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., Filipe, A. D. S., Wojcechowskyj, J. A., . . . Snell, G. (2021). Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. CELL, 184(5), 1171-+. doi:10.1016/j.cell.2021.01.037DOI: 10.1016/j.cell.2021.01.037
2020
Thompson, C. P., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenco, J., Penman, B. S., . . . Simmonds, P. (2020). Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. EUROSURVEILLANCE, 25(42), 33-41. doi:10.2807/1560-7917.ES.2020.25.42.2000685DOI: 10.2807/1560-7917.ES.2020.25.42.2000685
Drake, T. M., Docherty, A. B., Harrison, E. M., Quint, J. K., Adamali, H., Agnew, S., . . . ISARIC4C Investigators. (2020). Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study.. Am J Respir Crit Care Med. doi:10.1164/rccm.202007-2794OCDOI: 10.1164/rccm.202007-2794OC
Safety perspectives on presently considered drugs for the treatment of COVID‐19 (Journal article)
Penman, S. L., Kiy, R. T., Jensen, R. L., Beoku‐Betts, C., Alfirevic, A., Back, D., . . . Chadwick, A. E. (n.d.). Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology. doi:10.1111/bph.15204DOI: 10.1111/bph.15204
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. (Journal article)
Knight, S. R., Ho, A., Pius, R., Buchan, I., Carson, G., Drake, T. M., . . . ISARIC4C investigators. (2020). Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.. BMJ: British Medical Journal, 370. doi:10.1136/bmj.m3339DOI: 10.1136/bmj.m3339
Swann, O., Holden, K., Turtle, L., Pollock, L., Fairfield, C., Drake, T., . . . ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) Investigators. (2020). Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ, 370. doi:10.1136/bmj.m3249DOI: 10.1136/bmj.m3249
Penman, S. L., Jensen, R. L., Kiy, R. T., & Chadwick, A. E. (2020). Anti-Cancer Drugs: The mitochondrial paradox. eLife, 9. doi:10.7554/elife.59140DOI: 10.7554/elife.59140
